Concerning Public consultation on the Guideline on Risk proportionate approaches in clinical trials

The recommendation from the GCP-inspectors at the Danish Medicines Agency is that this guideline should not be finalized before the new version of the ICH-GCP is final. It is important to get alignment between the two documents – especially on central monitoring.

Kind regards
Lene Grejs Petersen

---

**Lene Grejs Petersen**
Cand.pharm, Chefkonsulent
*M.Sc.Pharm, Senior Adviser*

Lægemiddelstyrelsen
Lægemidlers Godkendelse & Tilgængelighed
Kliniske forsøg
*Danish Medicines Agency*
*Medicines Licensing & Availability*
*Clinical Trials*
T +45 4488 9595
dkma@dkma.dk
www.lmst.dk

LÆGEMIDDELSTYRELSEN
DANISH MEDICINES AGENCY